Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma

PET Clin. 2017 Jan;12(1):63-82. doi: 10.1016/j.cpet.2016.08.005. Epub 2016 Oct 6.


PET with fluorodeoxyglucose F 18 (18F FDG-PET) is a meaningful biomarker for the detection, targeted biopsy, and treatment of lymphoma. This article reviews the evolution of 18F FDG-PET as a putative biomarker for lymphoma and addresses the current capabilities, challenges, and opportunities to enable precision medicine practices for lymphoma. Precision nuclear medicine is driven by new imaging technologies and methodologies to more accurately detect malignant disease. Although quantitative assessment of response is limited, such technologies will enable a more precise metabolic mapping with much higher definition image detail and thus may make it a robust and valid quantitative response assessment methodology.

Keywords: Biomarker; Fluorodeoxyglucose; Lymphoma; Molecular imaging; Position emission tomography; Precision medicine.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Biopsy
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphoma / diagnostic imaging*
  • Lymphoma / therapy*
  • Molecular Imaging*
  • Molecular Targeted Therapy
  • Positron-Emission Tomography / methods*
  • Precision Medicine*
  • Predictive Value of Tests
  • Radiopharmaceuticals


  • Biomarkers, Tumor
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18